CN Bio ’s Post

If you are struggling with your hepatocytes, this webinar is for you!

📣 We are thrilled to announce our participation in the leading Spanish Hepatology Congress, by Asociación Española del Estudio del Hígado, where we have presented an original scientific poster.  🆕 This new research is the result of our R&D team, focused on developing an improved culture model using human precision-cut liver slices (hPCLS) to investigate the phenotype and functionality of the hepatic sinusoid in the context of chronic liver disease. By using our patent-protected chip with microfluidics, we are able to culture hPCLS with: ✔ Extended half-life, up to 7 days. ✔ Enhanced structural and functional integrity of the tissue. ✔ Prevention of the loss of the sinusoidal cell phenotype. This model represents a new research tool that brings us closer to clinical applications compared to traditional models 🚀  #AEEH2024 #Liver #Sinusoid #Hepatology #Cirrhosis #ACLD #PCLS #3Dmodel #Scientificinnovation

The first episode of "Making the Rounds: Geographic Atrophy" on MedPage Today regarding Monitoring and Managing Inflammation after Complement Inhibition for Geographic Atrophy is available with Andre Witkin of Tufts Medical Center and Chair of the ASRS – American Society of Retina Specialists Research and Safety in Therapeutics Committee. Concerning inflammation after Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol). #geographicatrophy https://lnkd.in/gkQueXAq

Fresh from the press!📰 Liver based microphysiological systems are absolutely fascinating! At DMPK, Sai Life Sciences Ltd., we're diving deep into this cutting-edge field. 🚀 Recent IQ MPS Affiliate survey results also highlighted liver MPS as one of the most popular models currently being explored in the industries for drug discovery! Interested in delving deeper into liver spheroids, liver organoids, and liver-on-chips? Our latest review article in Materials Today Bio offers a comprehensive overview of these models, detailing: 🔍Their unique capabilities and advantages over traditional in vitro liver models, 🔍Various validation studies by industry leaders using liver MPS, 🔍Their applications in predicting drug-induced liver injury (DILI), hepatic drug clearance, and bioavailability, 🔍 Various innovative scaling approaches for designing liver-on-chips, and 🔍 Current challenges and exciting future possibilities in the field! 🔗 The full article can be accessed here: https://lnkd.in/gD9Byudk #microphysiologicalsystems #organonchips #spheroids #organoids #ADME #drugdiscovery

Facing issues with sourcing high-quality human cells and tissues for your research? Look no further. LifeNet Health LifeSciences boasts the largest liver portfolio, featuring primary human hepatocytes (PHH), non-parenchymal cells (NPCs), and liver tissues, capable of meeting all your research needs. With 147 Donors and over 40,000 vials, LifeNet Health LifeSciences offers: 10 lots with over 900 PHH vials Over 45 lots for NPCs Over 250 lots for SFT/FFPE tissues Our extensive PHH portfolio increases the likelihood of offering lots that meet your specific research needs, supporting the relevance and translational potential of your studies. For more information on how we can help with your research needs, please visit the link below: LifeNet Health LifeSciences | Hepatocytes #lifesciences #liverresearch

Exciting news in @HEPJournal from director Arun Sanyal and a team of international all ⭐ colleagues! A milestone in non-invasively identifying at-risk MASH -- The metabolomics-advanced steatohepatitis fibrosis score (MASF score) can accurately identify metabolic dysfunction-associated steatohepatitis (MASLD) with ≥F2 fibrosis (at-risk MASH). 🔬The MASEF score, based on a unique combination of serum-based metabolomics and clinical data and developed by our partner, OWL Metabolomics, offers a new level of precision in diagnosing MASH. #liver https://bit.ly/47yPB4j

Check out our upcoming webinar on Cirrhosis together with Quentin Anstee.

Great preprint from Novartis Biomedical Research in which the authors demonstrate that ZNF469, a transcriptional regulator of collagen in human hepatic stellate cells (HSCs), is a determinant of NAFLD-associated liver fibrosis. In this study, the authors used the Vizgen #MERSCOPE #SpatialTranscriptomics platform powered by #MERFISH chemistry to profile 108 human liver biopsies. #MERSCOPE #MERFISH #SpatialTranscriptomics #SpatialBiology #SingleCell #SubCellular #OnlyRealDotsCount

📝 I’m thrilled to announce the publication of my first paper as a first author presenting the core findings of my PhD research on HHT and PAH in Angiogenesis journal! I’m grateful to all co-authors for this wonderful collaboration, especially Sabine Bailly and Agnès Desroches-Castan. 💡This work presents numerous interesting findings. Among them is the demonstration that ALK1 heterozygosity, which is responsible for HHT2 cases and few heritable PAH cases, does not impair the transcriptomic response of primary endothelial cells to the ALK1 ligands BMP9 and BMP10, with the exception of very few dysregulated targets… ⬇️ For a comprehensive view of the different findings and their implications, go ahead and dive into the full article below! #HHT #PAH #endothelialcells #RNAsequencing #vasculardiseases #raredisease #VACure #mscactions #CureHHT

Interesting cases using 18F-FAPI-74 Nouzha WiNMI leader,Group Expert of WiN Global EANM_WE,Vp #WiN Global,#WiNMI,#WiN for peace,#WiN YG,#WiN Africa,#WiN IAEA,#WiN France,#WiN Europe,#AMMN ,#SNMMI,#PSNM,#AI,#Nuclear Medicine,#Oncology,#Molecular Imaging,#Myocardial imaging,#ASCO,#EANM,#EANM_WE,#EANM_WE, #WARMTH, #alpha Therapy, #beta Nuclear Medicine therapyVp,#Oncidium,#ESMIT,#SFMN,#UCLA,#EJNMMI,#Americanoncologyinstitute,#Urology,#Prostate cancer,#CEA,#INSTN,#Clinical Nuclear Medicine ,#Endocrinology,#Parathyroid